Herantis Pharma Plc, Company release, 28 April 2021 at 3:30 PM EEST
Herantis Pharma Plc (“Herantis or the Company”), focusing on disease modifying therapies for debilitating neurodegenerative diseases, will host a virtual R&D Investor Day Tuesday 8 June, for investors, analysts and media, and other interested audiences.
The event is intended to provide an update on the Company’s disease modifying assets Cerebral Dopamine Neurotrophic Factor CDNF and xCDNF, that focus on improving neuronal survival and stop the progression of Parkinson’s and other neurodegenerative diseases. External experts will provide the latest perspectives on Parkinson’s disease and its treatment.
CDNF, Herantis’ lead program, is a protein that occurs naturally in the body whose normal role is to protect neurons by strongly preserving and restoring a key system in the body called proteostasis. Herantis is looking to harness this natural potential as a potent treatment for illnesses like Parkinson’s disease. xCDNF, Herantis’ second program, is a synthetic molecule using only the most active parts of the parent CDNF protein, specifically engineered to cross the Blood Brain Barrier (BBB) and retain the potency of CDNF. Current progress and latest data on both of these programs will be provided at the R &D Investor Day.
The agenda and details of how to join the meeting will be available in a press release and on the Company’s website (www.herantis.com) which will be issued closer to the time of the event.
For more information, please contact:
Julie Silber/Gabriela Urquilla
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400
Company website: www.herantis.com
About Herantis Pharma Plc
Herantis focuses on disease modifying therapies for debilitating neurodegenerative diseases by restoring the neuronal protective mechanism of proteostasis, a key system in neurodegenerative disease. Proteostasis regulates proteins within the body and influences the fate of every protein from synthesis to degradation. Its failure results in a vicious cycle of pathological accumulation of protein aggregates, neuroinflammation and various forms of cellular stress that is widely implicated with the development of many neurodegenerative diseases including Parkinson’s Disease, Alzheimer’s and other diseases. CDNF is a protein that occurs naturally in the body whose normal role is to protect neurons by balancing and supporting proteostasis, thereby preventing and counteracting disease generating mechanisms. Herantis is taking this natural ability and harnessing it as a treatment for neurodegenerative disease. CDNF – a biological protein – is Herantis’ lead program and a clinical stage asset; and xCDNF – a synthetic peptide version of CDNF – is Herantis’ follow-on program. Both CDNF and xCDNF have, via their multimodal mechanism of action, the potential improves neuronal survival and to stop the progression of Parkinson’s and other neurodegenerative disease and have a significant therapeutic impact on the lives of patients.
The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden. For more information, please visit https://www.herantis.com